Scientific Associate I (Assay Development and Biophysics)

UHN is Canada’s #1 hospital and the world’s #1 publicly funded hospital. With 10 sites and more than 44,000 TeamUHN members, UHN consists of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education and West Park Healthcare Centre. As Canada's top research hospital, the scope of biomedical research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. UHN has the largest hospital-based research program in Canada, with major research in neurosciences, cardiology, transplantation, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. UHN is a research hospital affiliated with the University of Toronto.

UHN’s vision is to build A Healthier World and it’s only because of the talented and dedicated people who work here that we are continually bringing that vision closer to reality.

www.uhn.ca

Position Summary

The Scientific Associate I, Assay Development and Biophysics, will contribute to an innovative, data-driven drug discovery programme supporting Target 2035, a global initiative to develop high-quality chemical tools for every protein in the human proteome. Reporting to the Principal Investigator, the successful candidate will perform biochemical and biophysical assays to validate protein-ligand interactions, analyse experimental results, and ensure high-quality data reporting to internal databases and external repositories. A particular focus of the role will be the development and application of surface plasmon resonance (SPR) assays to support hit validation, mechanism-of-action studies and chemical probe discovery.

This role also involves supporting assay development, training laboratory members, contributing to manuscripts and scientific reports, and collaborating across multidisciplinary teams to advance multiple open science drug discovery programmes. We work closely with academic institutions, pharmaceutical companies, technology developers and non-profit organisations to create innovative technologies, chemical tools and openly accessible datasets that make biomedical research faster, more collaborative and more impactful.

As part of the Centre for Collaborative Drug Discovery (C2D2) and the international Target 2035 community, our open science, milestone-driven research seeks to revolutionise and democratise drug discovery by generating high-quality reagents, data and technologies that enable the study of previously understudied proteins and accelerate the development of new medicines.

What We Offer

In addition to working alongside some of the most talented and inspiring healthcare professionals and researchers in the world, UHN offers a wide range of benefits, programs and perks. It is the comprehensiveness of these offerings that makes it a differentiating factor, allowing you to find value where it matters most to you, now and throughout your career at UHN.